Clinical Trials Browser

Phase 3 × Completed × carfilzomib × Clear all

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 2 FDA

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 3 FDA

Multiple Myeloma

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT01568866 2022-11-14

ENDEAVOR

Phase 3 Completed

929 enrolled 21 charts

Multiple Myeloma

NCT02412878 2022-09-23

ARROW

Phase 3 Completed

478 enrolled 17 charts

Multiple Myeloma

NCT01080391 2022-09-21

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Phase 3 Completed

792 enrolled 18 charts

Multiple Myeloma

NCT03029234 2022-05-25

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Phase 3 Completed

126 enrolled 30 charts

Multiple Myeloma, Recurrence

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT01302392 2017-05-02

FOCUS

Phase 3 Completed

315 enrolled 18 charts

Multiple Myeloma